How is the study funded?
Treatment for the study is provided by Novartis, the pharmaceutical company that produces inclisiran, which also helps with the costs of running the study, by a grant given to the University of Oxford. However, the trial is coordinated by Oxford University’s Clinical Trial Service Unit (CTSU) in collaboration with investigators at the TIMI Study Group at Harvard University (USA), ensuring independent oversight and rigorous scientific standards.